SRX246, also known as API-246, is a
small-molecule
Within the fields of molecular biology and pharmacology, a small molecule or micromolecule is a low molecular weight (≤ 1000 daltons) organic compound that may regulate a biological process, with a size on the order of 1 nm. Many drugs ar ...
,
centrally-active, highly-selective
vasopressin V1A receptor antagonist
An antagonist is a character in a story who is presented as the chief foe of the protagonist.
Etymology
The English word antagonist comes from the Greek ἀνταγωνιστής – ''antagonistēs'', "opponent, competitor, villain, enemy, riv ...
which is under investigation by Azevan Pharmaceuticals for the treatment of
affective and
anger disorders.
It is an
azetidinone derivative, and was developed from LY-307174 as a lead compound.
A
phase II Phase II, Phase 2 or Phase Two may refer to:
Media
* Marvel Cinematic Universe: Phase Two, six American superhero films from 2013–2015
* ''Star Trek: Phase II'', an unrealized television series based on the characters of Gene Roddenberry's ''S ...
activity trial of the drug in the treatment of adults with
intermittent explosive disorder is ongoing.
It is also being studied for the treatment of
post-traumatic stress disorder.
See also
*
List of investigational anxiolytics
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in paren ...
*
ABT-436
ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discon ...
*
Balovaptan
Balovaptan (; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism. As of August 2019, it is in a phase III clinical trial ...
*
Nelivaptan
Nelivaptan (INN) (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. The drug had entered clinical trials for treatment of anxiety and depression. In J ...
*
TS-121
References
External links
Azevan Pharmaceuticals, Inc. - Clinical CandidatesSRX-246 - AdisInsight
Lactams
Oxazolidines
Piperidines
Vasopressin receptor antagonists
{{nervous-system-drug-stub